CL2011003049A1 - Composicion quimica incluyendo un conjugado peg-lipido, que comprende una columna vertebral de glicerol, un grupo lipido unido por enlace covalente a la columna vertebral de glicerol, una cadena peg unida por enlace covalente a la columna vertebral del glicerol; y liposoma que comprende dicha composicion. - Google Patents

Composicion quimica incluyendo un conjugado peg-lipido, que comprende una columna vertebral de glicerol, un grupo lipido unido por enlace covalente a la columna vertebral de glicerol, una cadena peg unida por enlace covalente a la columna vertebral del glicerol; y liposoma que comprende dicha composicion.

Info

Publication number
CL2011003049A1
CL2011003049A1 CL2011003049A CL2011003049A CL2011003049A1 CL 2011003049 A1 CL2011003049 A1 CL 2011003049A1 CL 2011003049 A CL2011003049 A CL 2011003049A CL 2011003049 A CL2011003049 A CL 2011003049A CL 2011003049 A1 CL2011003049 A1 CL 2011003049A1
Authority
CL
Chile
Prior art keywords
glycerol backbone
covalently linked
peg
lipid
liposome
Prior art date
Application number
CL2011003049A
Other languages
English (en)
Inventor
Nian Keller Brian Charles Wu
Original Assignee
Wu Nian
Keller Brian Charles
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Wu Nian, Keller Brian Charles filed Critical Wu Nian
Publication of CL2011003049A1 publication Critical patent/CL2011003049A1/es

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/74—Synthetic polymeric materials
    • A61K31/765—Polymers containing oxygen
    • A61K31/77—Polymers containing oxygen of oxiranes
    • C—CHEMISTRY; METALLURGY
    • C08—ORGANIC MACROMOLECULAR COMPOUNDS; THEIR PREPARATION OR CHEMICAL WORKING-UP; COMPOSITIONS BASED THEREON
    • C08G—MACROMOLECULAR COMPOUNDS OBTAINED OTHERWISE THAN BY REACTIONS ONLY INVOLVING UNSATURATED CARBON-TO-CARBON BONDS
    • C08G65/00—Macromolecular compounds obtained by reactions forming an ether link in the main chain of the macromolecule
    • C08G65/02—Macromolecular compounds obtained by reactions forming an ether link in the main chain of the macromolecule from cyclic ethers by opening of the heterocyclic ring
    • C08G65/32—Polymers modified by chemical after-treatment
    • C08G65/329—Polymers modified by chemical after-treatment with organic compounds
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
    • A61K47/51—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
    • A61K47/56—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an organic macromolecular compound, e.g. an oligomeric, polymeric or dendrimeric molecule
    • A61K47/59—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an organic macromolecular compound, e.g. an oligomeric, polymeric or dendrimeric molecule obtained otherwise than by reactions only involving carbon-to-carbon unsaturated bonds, e.g. polyureas or polyurethanes
    • A61K47/60—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an organic macromolecular compound, e.g. an oligomeric, polymeric or dendrimeric molecule obtained otherwise than by reactions only involving carbon-to-carbon unsaturated bonds, e.g. polyureas or polyurethanes the organic macromolecular compound being a polyoxyalkylene oligomer, polymer or dendrimer, e.g. PEG, PPG, PEO or polyglycerol
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
    • A61K47/69—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the conjugate being characterised by physical or galenical forms, e.g. emulsion, particle, inclusion complex, stent or kit
    • A61K47/6905—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the conjugate being characterised by physical or galenical forms, e.g. emulsion, particle, inclusion complex, stent or kit the form being a colloid or an emulsion
    • A61K47/6911—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the conjugate being characterised by physical or galenical forms, e.g. emulsion, particle, inclusion complex, stent or kit the form being a colloid or an emulsion the form being a liposome
    • C—CHEMISTRY; METALLURGY
    • C08—ORGANIC MACROMOLECULAR COMPOUNDS; THEIR PREPARATION OR CHEMICAL WORKING-UP; COMPOSITIONS BASED THEREON
    • C08L—COMPOSITIONS OF MACROMOLECULAR COMPOUNDS
    • C08L63/00—Compositions of epoxy resins; Compositions of derivatives of epoxy resins
    • C08L63/10—Epoxy resins modified by unsaturated compounds
    • C—CHEMISTRY; METALLURGY
    • C08—ORGANIC MACROMOLECULAR COMPOUNDS; THEIR PREPARATION OR CHEMICAL WORKING-UP; COMPOSITIONS BASED THEREON
    • C08L—COMPOSITIONS OF MACROMOLECULAR COMPOUNDS
    • C08L2203/00—Applications
    • C08L2203/02—Applications for biomedical use

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Epidemiology (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Veterinary Medicine (AREA)
  • General Health & Medical Sciences (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Polymers & Plastics (AREA)
  • Organic Chemistry (AREA)
  • General Chemical & Material Sciences (AREA)
  • Dispersion Chemistry (AREA)
  • Medicinal Preparation (AREA)
  • Polyethers (AREA)

Abstract

Composición química incluyendo un conjugado peg-lípido, que comprende una columna vertebral de glicerol, un grupo lípido unido por enlace covalente a la columna vertebral de glicerol, una cadena peg unida por enlace covalente a la columna vertebral del glicerol; y liposoma que comprende dicha composición.
CL2011003049A 2009-06-02 2011-12-02 Composicion quimica incluyendo un conjugado peg-lipido, que comprende una columna vertebral de glicerol, un grupo lipido unido por enlace covalente a la columna vertebral de glicerol, una cadena peg unida por enlace covalente a la columna vertebral del glicerol; y liposoma que comprende dicha composicion. CL2011003049A1 (es)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US21762709P 2009-06-02 2009-06-02
US28406509P 2009-12-12 2009-12-12

Publications (1)

Publication Number Publication Date
CL2011003049A1 true CL2011003049A1 (es) 2012-07-13

Family

ID=43298359

Family Applications (1)

Application Number Title Priority Date Filing Date
CL2011003049A CL2011003049A1 (es) 2009-06-02 2011-12-02 Composicion quimica incluyendo un conjugado peg-lipido, que comprende una columna vertebral de glicerol, un grupo lipido unido por enlace covalente a la columna vertebral de glicerol, una cadena peg unida por enlace covalente a la columna vertebral del glicerol; y liposoma que comprende dicha composicion.

Country Status (15)

Country Link
US (1) US20110040113A1 (es)
EP (1) EP2437756A2 (es)
JP (1) JP2012528857A (es)
KR (1) KR20120039564A (es)
CN (1) CN102665685A (es)
AP (1) AP2012006053A0 (es)
AU (1) AU2010257181A1 (es)
BR (1) BRPI1010175A2 (es)
CA (1) CA2763819A1 (es)
CL (1) CL2011003049A1 (es)
CO (1) CO6511284A2 (es)
IL (1) IL216719A0 (es)
MX (1) MX2011012823A (es)
WO (1) WO2010141069A2 (es)
ZA (1) ZA201109366B (es)

Families Citing this family (54)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US9393315B2 (en) 2011-06-08 2016-07-19 Nitto Denko Corporation Compounds for targeting drug delivery and enhancing siRNA activity
US20120202890A1 (en) * 2011-02-08 2012-08-09 Nian Wu Polymer-carbohydrate-lipid conjugates
WO2012122144A1 (en) * 2011-03-07 2012-09-13 Wu Nian Highly monodisperse branched peg-lipid conjugates
US10196637B2 (en) 2011-06-08 2019-02-05 Nitto Denko Corporation Retinoid-lipid drug carrier
US8883177B2 (en) * 2011-06-28 2014-11-11 Nian Wu Pharmaceutical compositions for parenteral administration
JP6051758B2 (ja) * 2011-10-17 2016-12-27 日油株式会社 ジアシルグリセロールと結合した分岐型ポリエチレングリコール、その製造方法およびポリエチレングリコール修飾リポソーム
ES2881671T3 (es) * 2012-08-21 2021-11-30 Opko Pharmaceuticals Llc Formulaciones de liposomas
US11458199B2 (en) 2012-08-21 2022-10-04 Opko Pharmaceuticals, Llc Liposome formulations
WO2014032026A1 (en) 2012-08-24 2014-02-27 Mitra Ashim K Ophthalmic formulation of polyoxyl lipid or polyoxyl fatty acid and treatment of ocular conditions
WO2015021044A1 (en) * 2013-08-05 2015-02-12 University Of Rochester Compositions and methods for stimuli-responsive release of a therapeutic agent
JP6646578B2 (ja) * 2013-12-05 2020-02-14 ウー, ニエンWU, Nian 薬物転送技術のための高分子−炭水化物共役体
ES2708360T3 (es) * 2013-12-20 2019-04-09 Hoffmann La Roche Compuestos que comprenden uno o más dominios hidrófobos y un dominio hidrófilo que comprende restos de PEG, útiles para unir células
EP3084433B1 (en) 2013-12-20 2020-03-18 Roche Diagnostics GmbH Method of immobilizing a cell on a support using compounds comprising a polyethylene glycol moiety
JP6461973B2 (ja) * 2013-12-20 2019-01-30 エフ．ホフマン−ラ ロシュ アーゲーＦ． Ｈｏｆｆｍａｎｎ−Ｌａ Ｒｏｃｈｅ Ａｋｔｉｅｎｇｅｓｅｌｌｓｃｈａｆｔ ２以上の疎水性ドメインおよびｐｅｇ部分を含む親水性ドメインを含む化合物の、細胞の安定化のための使用
EP3229842B1 (en) 2014-12-08 2022-07-06 The Board of Regents of The University of Texas System Lipocationic polymers and uses thereof
US10064954B2 (en) * 2015-06-23 2018-09-04 Nian Wu Polymer-cyclodextrin-lipid conjugates
CN108271360B (zh) 2015-09-14 2023-01-24 得克萨斯州大学系统董事会 亲脂阳离子树枝状聚合物及其用途
PL3373976T3 (pl) 2015-11-10 2024-06-24 Sun Pharmaceutical Industries Limited Preparaty do stosowania miejscowego i ich zastosowanie
CA3007955A1 (en) 2015-12-10 2017-06-15 Modernatx, Inc. Lipid nanoparticles for delivery of therapeutic agents
CN106905120B (zh) * 2015-12-21 2020-04-28 北京键凯科技股份有限公司 Y型多缩乙二醇衍生物及其制备方法
MX2018010395A (es) 2016-02-29 2018-11-29 Sun Pharma Global Fze Formulaciones topicas que contienen cliclosporina y usos de las mismas.
US20170354672A1 (en) 2016-05-16 2017-12-14 The Board Of Regents Of The University Of Texas System Compositions for the delivery of trna as nanoparticles and methods of use therewith
AU2017267634C1 (en) 2016-05-16 2022-05-26 The Board Of Regents Of The University Of Texas System Cationic sulfonamide amino lipids and amphiphilic zwitterionic amino lipids
WO2018170270A1 (en) 2017-03-15 2018-09-20 Modernatx, Inc. Varicella zoster virus (vzv) vaccine
US11905367B2 (en) 2018-03-20 2024-02-20 Nof Corporation Branched monodispersed polyethylene glycol, intermediate and methods for producing same
EP3778703B1 (en) * 2018-03-29 2022-08-03 NOF Corporation Method for purifying trityl group-containing monodispersed polyethylene glycol
WO2019191597A1 (en) * 2018-03-30 2019-10-03 The Board Of Regents Of The University Of Oklahoma Very long chain saturated fatty acid compounds, compositions containing same, and methods of use
US12357580B2 (en) 2018-06-19 2025-07-15 The Board Of Regents Of The University Of Texas System Lipid nanoparticle compositions for delivery of mRNA and long nucleic acids
GB2592504B (en) 2018-09-04 2023-02-15 Univ Texas Compositions and methods for organ specific delivery of nucleic acids
EP3846822A4 (en) 2018-09-04 2022-07-06 The Board Of Regents Of The University Of Texas System COMPOSITIONS AND METHODS FOR ORGAN-SPECIFIC DELIVERY OF NUCLEIC ACIDS
AU2019345067A1 (en) 2018-09-19 2021-04-08 Modernatx, Inc. High-purity peg lipids and uses thereof
JP6805385B1 (ja) * 2020-08-31 2020-12-23 ジェイ−ネットワーク，インコーポレイテッド 表皮内の保湿関連物質の発現増強剤
CN116615235A (zh) 2020-10-09 2023-08-18 得克萨斯州大学系统董事会 融合前稳定的hmpv f蛋白
JP6860739B1 (ja) * 2020-11-20 2021-04-21 ジェイ−ネットワーク，インコーポレイテッド 表皮内の抗酸化物質の発現増強剤
WO2022131220A1 (ja) * 2020-12-15 2022-06-23 東洋紡株式会社 ポリエステル樹脂
CN114685778B (zh) * 2020-12-30 2023-10-17 苏州艾博生物科技有限公司 长循环阳离子脂质体的合成方法
CN117157101A (zh) 2021-02-08 2023-12-01 德克萨斯大学系统董事会 不饱和的树枝状聚合物组合物、有关的制剂、及其使用方法
KR20230175196A (ko) 2021-03-23 2023-12-29 리코드 테라퓨틱스, 인크. 폴리뉴클레오티드 조성물, 관련된 제제, 및 이의 사용 방법
WO2022226344A1 (en) 2021-04-22 2022-10-27 The Board Of Regents Of The University Of Texas System All-in-one dendrimer-based lipid nanoparticles enable precise hdr-mediated gene editing in vivo
CN114276535B (zh) 2021-06-30 2022-06-21 天津键凯科技有限公司 聚乙二醇脂质及其应用
CN113461929B (zh) * 2021-07-13 2023-04-21 浙江倍合德制药有限公司 一种tpgs系列产品的精制提纯方法
CN116410460B (zh) * 2021-12-29 2025-08-05 辅必成（上海）医药科技有限公司 一种1,2-二肉豆蔻酰-rac-甘油-3-甲氧基聚乙二醇2000的制备方法
CN114507342B (zh) * 2022-03-18 2024-03-19 江苏东南纳米材料有限公司 一种1,2-二肉豆蔻酰-rac-甘油-3-甲氧基聚乙二醇及其中间体的制备方法
EP4504265A1 (en) * 2022-04-05 2025-02-12 Capstan Therapeutics, Inc. Peg-lipids and lipid nanoparticles
CN114524943B (zh) * 2022-04-22 2022-09-16 天津凯莱英制药有限公司 聚乙二醇-甘油衍生物及其中间体各自的制备方法
CN117003807A (zh) * 2022-04-28 2023-11-07 北京科兴中维生物技术有限公司 一种结构脂质化合物及其制备方法和用途
JP2025539101A (ja) * 2022-11-15 2025-12-03 エボニック オペレーションズ ゲーエムベーハー ポリオキシアルキレンがｃ１～ｃ３－アルキルオキシメチル側鎖を有するポリ（エチレンオキシド）である、ポリオキシアルキレン－１，２－ジミリストイル－グリセロール化合物
EP4630057A1 (en) 2022-12-08 2025-10-15 Recode Therapeutics, Inc. Lipid nanoparticle compositions and uses thereof
EP4648796A2 (en) 2023-01-09 2025-11-19 Board of Regents, The University of Texas System Prefusion-stabilized human parainfluenza virus 3 f proteins
CN116178733B (zh) * 2023-03-03 2023-08-01 浙江博美生物技术有限公司 一种基于三官能团氨基酸的支化单分散peg衍生物、制备方法和应用
US12553042B2 (en) 2023-12-01 2026-02-17 Recode Therapeutics, Inc. Method for quantifying an amount of capped messenger RNA
US12364773B2 (en) 2023-12-01 2025-07-22 Recode Therapeutics, Inc. Lipid nanoparticle compositions and uses thereof
US12539279B2 (en) 2023-12-11 2026-02-03 The Governing Council Of The University Of Toronto Supramolecular ionizable lipid molecules with heteroatomic tuning for nucleic acid delivery
WO2025137646A1 (en) 2023-12-22 2025-06-26 Recode Therapeutics, Inc. Gene editing methods and compositions for treating cystic fibrosis

Family Cites Families (6)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5827533A (en) * 1997-02-06 1998-10-27 Duke University Liposomes containing active agents aggregated with lipid surfactants
US7141552B2 (en) * 2000-01-10 2006-11-28 Yissum Research Development Company Of The Hebrew University Of Jerusalem Use of lipid conjugates in the treatment of diseases
CN1882693B (zh) * 2003-09-15 2012-08-15 普洛体维生物治疗公司 聚乙二醇修饰的脂质化合物及其应用
WO2006007712A1 (en) * 2004-07-19 2006-01-26 Protiva Biotherapeutics, Inc. Methods comprising polyethylene glycol-lipid conjugates for delivery of therapeutic agents
CA3218940A1 (en) * 2004-11-12 2006-05-18 Cambridge University Technical Services Ltd. Methods and means related to cancer stem cells
CN101909581B (zh) * 2007-11-14 2012-11-14 加利福尼亚大学董事会 固醇修饰的两亲脂质

Also Published As

Publication number Publication date
MX2011012823A (es) 2012-06-25
KR20120039564A (ko) 2012-04-25
JP2012528857A (ja) 2012-11-15
CN102665685A (zh) 2012-09-12
WO2010141069A2 (en) 2010-12-09
ZA201109366B (en) 2012-08-29
US20110040113A1 (en) 2011-02-17
IL216719A0 (en) 2012-02-29
WO2010141069A3 (en) 2012-04-12
BRPI1010175A2 (pt) 2016-03-29
AU2010257181A1 (en) 2012-01-12
EP2437756A2 (en) 2012-04-11
CA2763819A1 (en) 2010-12-09
CO6511284A2 (es) 2012-08-31
AP2012006053A0 (en) 2012-02-29

Similar Documents

Publication Publication Date Title
CY1115254T1 (el) Φαρμακευτικα διαλυματα, διαδικασιες για την παρασκευη τους και θεραπευτικες χρησεις
CO6382137A2 (es) Oligonucleótidos inmunoestimuladores
NI201200038A (es) Conjugados de niacina y ácidos grasos y sus usos
CR20120042A (es) Inmunoconjugados dirigidos
ECSP13011139A (es) Anticuerpos contra la angiopoyetina 2 humana
SI2200588T1 (sl) Sestavki, ki obsegajo lipofilne aktivne spojine, in postopek za njihovo pripravo
BRPI0910503A2 (pt) compostos, composições farmacêuticas e respectivos usos.
EP2401264A4 (en) PEPTOID OLIGOMERS, PHARMACEUTICAL COMPOSITIONS AND METHOD FOR THEIR USE
BRPI1010175A2 (pt) "composição química que inclui um conjugado de lipídio-peg e lipossoma"
MX2010005346A (es) Composiciones farmaceuticas.
PH12012500754A1 (en) Pharmaceutical composition comprising oligopeptides
CR20110649A (es) Composiciones solidas que comprenden acido 5-aminolevulinico
CL2012003039A1 (es) Polietilenglicol conjugado a factor viii mediante un grupo conector; composicion farmaceutica que comprende dicho polietilenglicol conjugado; uso de dicha composicion para tratamiento de una enfermedad o trauma de la coagulacion de la sangre.
CL2012000744A1 (es) Proceso para preparar un conjugado de polisacáridos capsulares tipo 5 o tipo 8 de s. aureus y una molécula transportadora; conjugado de polisacáridos; y composición inmunogénica que lo comprende.
CL2009001804A1 (es) Uso de un copolimero de vinilamina-vinilformamida y un portador para preparar una composicion destinada a fortalecer las fibras queratinosas.
BR112015004515A2 (pt) composição imunogênica
CL2013000237A1 (es) Composicion farmaceutica que comprende un sirna dirigido a vegfa; y metodo para disminuir la expresion de vegfa in vivo.
BR112013014941A2 (pt) produto da reação de oxidação do extrato de lúpulo, método para sua preparação e seu uso
CY1118461T1 (el) Φαρμακευτικες συνθεσεις που περιλαμβανουν αναστολεα αρωματασης
CY1116538T1 (el) Αναλογα ολιγονουκλεοτιδιου τροποποιημενα με φωσφορικο με ανοσοδιεγερτικη δραστικοτητα
BRPI1007242A2 (pt) máquina compacta transportável para preparação de bebida
CY1125270T1 (el) Βελτιωσεις σε και σχετιζομενες με συνθεσεις
CO6280503A2 (es) Conjugados de neurturina novedosas para uso farmaceutico
DK2240487T3 (da) Triazolopyridaziner som para-inhibitorer, fremstilling og anvendelse heraf som lægemiddel
ECSP10010661A (es) Dronedarona para la prevención de la cardioversión